Sarizotan - Newron Pharmaceuticals

Drug Profile

Sarizotan - Newron Pharmaceuticals

Alternative Names: EMD 128130

Latest Information Update: 18 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Newron Pharmaceuticals
  • Class Antiparkinsonians; Antipsychotics
  • Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Rett syndrome
  • Discontinued Drug-induced dyskinesia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Jun 2018 Independent international safety monitoring board recommends to continue the STARS trial without any modification
  • 24 Oct 2016 Phase-II/III clinical trials in Rett syndrome (In adolescents, In adults, In children) in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top